German radiopharmaceutical group ITM Isotope Technologies Munich has secured 25 million euros in a private equity funding round that it plans to put toward oncologic radioisotope research and development.
The funds add to ITM's coffers: In April, it announced a 90-million-euro convertible loan agreement.
The company's lead radioisotope candidate is Lu-177 Edotreotide, which is in a phase III trial for gastroenteropancreatic neuroendocrine tumors, it said.
